A recent systematic review and patient-level meta-analysis published in The Lancet reported a slightly lower incidence of subsequent myocardial infarction or stroke in patients on clopidogrel, irrespective of the clinical presentation of the preceding event or the subsequent treatment (stenting, bypass or medical therapy alone). Other benefits and risks of aspirin and clopidogrel were similar. Some commentators have suggested that clopidogrel may be a better choice for secondary prevention of CAD in those on medical therapy alone, whereas for those who have had stents or bypass surgery, there are many studies demonstrating the benefits of aspirin and either would be a reasonable choice.

Click here to read the abstract.